



DexTech

Know-how in Translational Research

Press release 2021-02-01

DexTech receives positive results regarding multiple myeloma

DexTech can announce that the company is expanding its preclinical program to also include research into the effect of OsteoDex on multiple myeloma, (MM), in vitro, cell cultures. MM is a malignant tumor disease of the bone marrow, which causes the skeleton to break down. MM is an incurable disease where a number of different treatments are used to slow down the process. The treatments often have severe side effects.

The company sees OsteoDex as very promising for the treatment of MM based on its mechanism of action and mild side effects. In summary, a potent treatment effect is seen, even at low concentrations of OsteoDex. Effect at low concentration is an important result in in vitro testing and indicates possible effect in vivo (in living organism). The observed cell killing effect is superior to the compared substance, Melphalan, which is a standard drug in the treatment of MM.

The investment is made as an important part of the Company's strategy to broaden interest in OsteoDex's opportunities, excluding prostate cancer, and as a targeted part of the strategy for out-licensing. Despite delays due to the Corona pandemic, the company looks forward with great confidence to the continued work in 2021.

For further information

Gösta Lundgren - CFO & Investor Relations

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on February 1, 2021.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.